Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure.

BACKGROUND During therapy to relieve congestion in advanced heart failure, cardiac filling pressures can frequently be reduced to near-normal levels with improved cardiac output. It is not known whether the early hemodynamic improvement and drug response can be maintained long term. METHODS AND RESULTS After referral for cardiac transplantation with initially severe hemodynamic decompensation, 25 patients survived without transplantation to undergo hemodynamic reassessment after 8+/-6 months of treatment tailored to early hemodynamic response. Initial changes included net diuresis, increased ACE inhibitor doses, and frequent addition of nitrates. After 8 months of therapy, early reductions were sustained for pulmonary wedge pressure (24+/-9 to 15+/-5 mm Hg early; 12+/-6 mm Hg late) and systemic vascular resistance (1651+/-369 to 1207+/-281 dynes x s(-1) x cm(-5) early; 1003+/-193 dynes x s(-1) x cm(-5) late). Acute response to doses persisted at reevaluation. Sustained reduction in filling pressures was accompanied by a progressive increase in stroke volume (42+/-10 to 56+/-13 mL early; 79+/-20 mL late), improved functional class, and freedom from resting symptoms. Study design did not control for amiodarone, which was initiated for arrhythmias in 12 patients and associated with greater improvement in cardiac index (1.8 to 3.2 L min(-1) x m(-2) late on amiodarone versus 2.0 to 2.6 L x min(-1) x m(-2), P<.05). CONCLUSIONS During chronic therapy tailored to early hemodynamic response in advanced heart failure, acute vasodilator response persists, and near-normal filling pressures can be maintained in patients who survive without transplantation. Stroke volumes at low filling pressures increase further over time. Chronic hemodynamic improvement was accompanied by symptomatic improvement, but the contributions of the monitored hemodynamic approach, increased vasodilator doses, and comprehensive outpatient management have not yet been established.

[1]  D R Nul,et al.  Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicéntricos en Argentina. , 1997, Journal of the American College of Cardiology.

[2]  T. Nozawa,et al.  Energetically optimal left ventricular pressure for the failing human heart. , 1996, Circulation.

[3]  R. Carney,et al.  A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. , 1995, The New England journal of medicine.

[4]  P C Deedwania,et al.  Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. , 1995, The New England journal of medicine.

[5]  G. Fonarow,et al.  Improvement in exercise capacity of candidates awaiting heart transplantation. , 1995, Journal of the American College of Cardiology.

[6]  H. Doval,et al.  Randomised trial of low-dose amiodarone in severe congestive heart failure , 1994, The Lancet.

[7]  M. Fisher,et al.  Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors. , 1993, Journal of the American College of Cardiology.

[8]  M. Anguita,et al.  Clinical and hemodynamic predictors of survival in patients aged < 65 years with severe congestive heart failure secondary to ischemic or nonischemic dilated cardiomyopathy. , 1993, The American journal of cardiology.

[9]  D. Renlund,et al.  Lisinopril Lowers Cardiac Adrenergic Drive and Increases, 8‐Recept or Density in the Failing Human Heart , 1993, Circulation.

[10]  F. Tristani,et al.  Hydralazine and Isosorbide Dinitrate Combination Improves Exercise Tolerance in Heart Failure Results from V‐HeFT I and V‐HeFT II , 1993, Circulation.

[11]  R. Bolman,et al.  Trends in patient selection for heart transplantation. , 1993, Journal of the American College of Cardiology.

[12]  U. Elkayam,et al.  Persistent hemodynamic improvement with short-term nitrate therapy in patients with chronic congestive heart failure already treated with captopril. , 1992, The American journal of cardiology.

[13]  S. Yusuf,et al.  Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. , 1992, Circulation.

[14]  S. Yusuf,et al.  Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril on the Long‐term: Progression of Left Ventricular Dysfunction in Patients With Heart Failure , 1992, Circulation.

[15]  F. Cobb,et al.  Central hemodynamic response to exercise in patients with chronic heart failure. , 1992, Chest.

[16]  P. Poole‐Wilson,et al.  Blood flow and skeletal muscle in patients with heart failure. , 1992, Chest.

[17]  M. Kukin Vasodilator therapy and survival in chronic congestive heart failure. , 1992, Journal of the American College of Cardiology.

[18]  M. Luu,et al.  Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. , 1992, Journal of the American College of Cardiology.

[19]  J. Juggi,et al.  Vasodilator therapy: interaction of nitrates with angiotensin-converting enzyme inhibitors. , 1991, The Canadian journal of cardiology.

[20]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[21]  K. Weber,et al.  Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.

[22]  J R Wilson,et al.  Value of Peak Exercise Oxygen Consumption for Optimal Timing of Cardiac Transplantation in Ambulatory Patients With Heart Failure , 1991, Circulation.

[23]  M. Woo,et al.  Sustained reduction in valvular regurgitation and atrial volumes with tailored vasodilator therapy in advanced congestive heart failure secondary to dilated (ischemic or idiopathic) cardiomyopathy. , 1991, The American journal of cardiology.

[24]  W. Grossman,et al.  Effects of coronary venous pressure on left ventricular diastolic distensibility. , 1990, Circulation research.

[25]  A. Katz Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. , 1990, The New England journal of medicine.

[26]  M. Schwaiger,et al.  Afterload reduction with vasodilators and diuretics decreases mitral regurgitation during upright exercise in advanced heart failure. , 1990, Journal of the American College of Cardiology.

[27]  L. Stevenson,et al.  Exercise capacity for survivors of cardiac transplantation or sustained medical therapy for stable heart failure. , 1990, Circulation.

[28]  A. Maisel,et al.  Regulation of cardiac beta-adrenergic receptors by captopril. Implications for congestive heart failure. , 1989, Circulation.

[29]  R. Cody,et al.  Age-related hemodynamic, renal, and hormonal differences among patients with congestive heart failure. , 1989, Archives of internal medicine.

[30]  H. Drexler,et al.  Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebo-controlled trial. , 1989, Circulation.

[31]  R. Dietz,et al.  Influence of captopril on the arterial baroreceptor reflex in patients with heart failure. , 1988, European heart journal.

[32]  M. Schwaiger,et al.  Effects of afterload reduction (diuretics and vasodilators) on left ventricular volume and mitral regurgitation in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1987, The American journal of cardiology.

[33]  L. Stevenson,et al.  Maintenance of cardiac output with normal filling pressures in patients with dilated heart failure. , 1986, Circulation.

[34]  S. R. Cohen,et al.  Contribution of reduced mitral regurgitant volume to vasodilator effect in severe left ventricular failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. , 1986, The American journal of cardiology.

[35]  C. Leddy,et al.  Hemodynamic effects of vasodilators and long-term response in heart failure. , 1984, Journal of the American College of Cardiology.

[36]  W. Laskey,et al.  Matching of myocardial oxygen consumption to mechanical load in human left ventricular hypertrophy and dysfunction. , 1984, Journal of the American College of Cardiology.

[37]  B. Massie,et al.  Controlled Trial of Captopril in Chronic Heart Failure: A Rest and Exercise Hemodynamic Study , 1983, Circulation.

[38]  R. Magorien,et al.  Improved Exercise Capacity and Differing Arterial and Venous Tolerance During Chronic Isosorbide Dinitrate Therapy for Congestive Heart Failure , 1983, Circulation.

[39]  G. Francis,et al.  Medical management of terminal cardiomyopathy , 1982 .

[40]  B. Massie,et al.  Long‐term Vasodilator Therapy for Heart Failure: Clinical Response and its Relationship to Hemodynamic Measurements , 1981, Circulation.

[41]  J. Cohn,et al.  Treatment of refractory heart failure with infusion of nitroprusside. , 1974, The New England journal of medicine.

[42]  W. Parmley,et al.  Beneficial Effects of Vasodilator Agents in Severe Mitral Regurgitation Due to Dysfunction of Subvalvar Apparatus , 1973, Circulation.

[43]  R. Russell,et al.  Effects of increasing left ventricular filling pressure in patients with acute myocardial infarction , 1970 .